Triple-negative breast cancer
Disease4 papers5 findings
- Humans1
Associations
5Obesity
upin humans1
1 study
Obesity
upin humans1
Obesity is associated with triple-negative breast cancer in humans.
Review
Obesity-related Metabolic Dysfunction and Triple-negative Breast Cancer: Epidemiologic Signals, Mechanistic Pathways, and Opportunities for Prevention · Current obesity reports · 11 Sep 2026
Mean asymptomatic time
downin silico1
1 study
Mean asymptomatic time
downin silico1
Triple-negative breast cancer is associated with mean asymptomatic time in silico (4.5 vs 7.6 vs 11.8 years).
In silico
Estimation of Subtype-Specific Tumour Growth Rate Distributions and Interval Cancer Proportions in Breast Cancer Using Biology-Inspired Natural History Models · International journal of cancer · 28 Aug 2026
Tumour mean doubling time
downin silico1
1 study
Tumour mean doubling time
downin silico1
Triple-negative breast cancer is associated with tumour mean doubling time in silico (126 days vs 203 days vs 332 days).
In silico
Estimation of Subtype-Specific Tumour Growth Rate Distributions and Interval Cancer Proportions in Breast Cancer Using Biology-Inspired Natural History Models · International journal of cancer · 28 Aug 2026
Proportion of interval cancers
upin silico1
1 study
Proportion of interval cancers
upin silico1
Triple-negative breast cancer is associated with proportion of interval cancers in silico (48.9% vs 32.3% vs 22.0%).
In silicoregular screening attenders
Estimation of Subtype-Specific Tumour Growth Rate Distributions and Interval Cancer Proportions in Breast Cancer Using Biology-Inspired Natural History Models · International journal of cancer · 28 Aug 2026
BRCA1
upin humans1
1 study
BRCA1
upin humans1
BRCA1 is associated with triple-negative breast cancer in humans.
Reviewfemales
[BRCA1 Gene's Mutations And Hereditary Breast Cancer: Genetic, Biological, And Clinical Aspects] · Le Mali medical · 19 Jan 2026
Trial sponsors
Company2 trialsPhase 3416 people
Company1 trialPhase 3634 people
Company1 trialPhase 3441 people
Company2 trialsPhase 2262 people
Company1 trialPhase 1/2557 people
Company1 trialPhase 1/231 people
Company1 trialPhase 1/210 people
Company1 trialPhase 1/29 people
Funding
Innovative UK£45.5kNational Cancer InstituteUS$26.4k2 grants since 2024
National Cancer InstituteVanderbilt UniversityUS$26.4k2024–2026
Innovative UKExonostic£45.5k2025–2026